The trading price of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) closed higher on Tuesday, May 23, closing at $8.77, 2.33% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $8.56 and $8.92. In examining the 52-week price action we see that the stock hit a 52-week high of $15.43 and a 52-week low of $7.20. Over the past month, the stock has gained 15.24% in value.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
BioCryst Pharmaceuticals Inc., whose market valuation is $1.64 billion at the time of this writing, is expected to release its quarterly earnings report Aug 02, 2023 – Aug 07, 2023. Investors’ optimism about the company’s current quarter earnings report is understandable.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of BioCryst Pharmaceuticals Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest BCRX has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 100% Sell.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned BCRX a recommendation rating is 12. Out of them, 5 rate it a Hold, while 7 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged BioCryst Pharmaceuticals Inc. (BCRX) as Underweight, while 0 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that BCRX’s price is currently 7.02% off the SMA20 and 7.07% off the SMA50. The RSI metric on the 14-day chart is currently showing 60.19, and weekly volatility stands at 2.88%. When measured over the past 30 days, the indicator reaches 3.87%. BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)’s beta value is currently sitting at 1.97, while the Average True Range indicator is currently displaying 0.34. With analysts defining $8.00-$30.00 as the low and high price targets, we arrive at a consensus price target of $14.95 for the trailing 12-month period. The current price is about 8.78% off the estimated low and -242.08% off the forecast high, based on this estimate. Investors will be thrilled if BCRX’s share price rises to $13.00, which is the median consensus price. At that level, BCRX’s share price would be -48.23% below current price.
To see how BioCryst Pharmaceuticals Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: BCRX stock’s performance was 2.33% in the latest trading, and -3.63% in the past year, while CEL-SCI Corporation (CVM) has traded -9.26% on the day and positioned -21.73% lower than it was a year ago. Another comparable company Emergent BioSolutions Inc. (EBS) saw its stock close 1.98% higher in the most recent trading session but was down -75.26% in a year. Furthermore, Sarepta Therapeutics Inc. (SRPT) showed a decrease of -1.45% on the day while its price kept inclining at 112.24% over the past year. Also in last trading session, the S&P 500 Index has plunged -1.12%, while the Dow Jones Industrial also saw a negative session, down -0.69% on the day.
An evaluation of the daily trading volume of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) indicates that the 3-month average is 2.89 million. However, this figure has increased over the past 10 days to an average of 2.31 million.
Currently, records show that 188.51 million of the company’s shares remain outstanding. The insiders hold 0.80% of outstanding shares, whereas institutions hold 81.10%. The stats also highlight that short interest as of Apr 27, 2023, stood at 31.2 million shares, resulting in a short ratio of 11.2 at that time. From this, we can conclude that short interest is 16.52% of the company’s total outstanding shares. It is noteworthy that short shares in April were down slightly from the previous month’s figure, which was 31.22 million. However, since the stock’s price has seen -23.61% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
